Novacyt (FR:ALNOV)
:ALNOV
Want to see FR:ALNOV full AI Analyst Report?
ALNOV Stock Chart & Stats
€0.40
<€0.01(0.56%)
At close: 4:00 PM EST
€0.40
<€0.01(0.56%)
Day’s Range― - ―
52-Week Range€0.29 - €1.04
Previous CloseN/A
Volume192.22K
Average Volume (3M)141.10K
Market Cap
€29.76M
Enterprise Value€28.35M
Total Cash (Recent Filing)€19.14M
Total Debt (Recent Filing)€10.44M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding72,588,090
10 Day Avg. Volume69,615
30 Day Avg. Volume141,103
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.03
Price to Sales (P/S)1.18
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€30.58M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high gross margins driven by PCR/RUO product mix (Primerdesign >80%) create durable cash generation per unit sold. This margin profile supports funding R&D and SG&A while lowering the revenue threshold required to reach EBITDA profitability, improving long-term resilience.
Instrument-led Pull-throughGrowing instrument sales (LightBench) build an installed base that produces recurring reagent and consumable demand. Instrument-led models create multi-year revenue visibility via consumable pull-through, improving lifetime customer value and providing structural revenue diversification versus one-off kit sales.
Regulatory Moat (IVDR)IVDR accreditation raises barriers to entry and supports preferential adoption in regulated European markets. Certification reduces competitive pressure, underpins long-term contractability and pricing power for certified assays, and enhances durability of clinical revenue streams over 12–24+ months.
Bears Say
Structural UnprofitabilityPersistent losses over multiple years indicate the current revenue base and cost structure have not scaled to sustainable profitability. Continued negative operating results will require sustained margin improvement or revenue expansion to avoid repeated reliance on external funding, limiting strategic flexibility.
Weak Cash Generation / Liquidity RiskMaterial cash depletion and sub‑£1m monthly burn leave limited runway absent forecast execution. Liquidity pressure increases the probability of dilutive financing or constrained investment in growth initiatives, which can slow product rollouts and impair the path to sustained profitability.
Large Impairments & Exceptional ChargesSignificant non‑cash impairments signal prior overpayment or weaker asset economics and erode equity headroom. They reflect integration or demand shortfalls and increase scrutiny on M&A discipline, potentially limiting confidence in future acquisition-led growth and reducing balance sheet flexibility.
Novacyt News
ALNOV FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.29 and its highest was €1.04 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €29.76M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Sep 24, 2026 which is in 103 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Apr 30, 2026. The company reported -€0.269 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.269.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -€0.269 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.514%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in FR:ALNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
ALNOV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.View all FR:ALNOV earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―
Options Prices
Currently, No data available
---